262 related articles for article (PubMed ID: 29509560)
1. Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis: A Real-World Evidence Study With Ustekinumab.
Queiro R; Brandy A; Rosado MC; Lorenzo A; Coto P; Carriles C; Alperi M; Ballina J
J Clin Rheumatol; 2018 Oct; 24(7):381-384. PubMed ID: 29509560
[TBL] [Abstract][Full Text] [Related]
2. Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.
Napolitano M; Costa L; Caso F; Megna M; Scarpa R; Balato N; Ayala F; Balato A
Clin Rheumatol; 2017 Jul; 36(7):1589-1593. PubMed ID: 28567556
[TBL] [Abstract][Full Text] [Related]
3. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study.
Queiro R; Cañete JD; Montilla C; Abad M; Montoro M; Gómez S; Cábez A;
Arthritis Res Ther; 2017 Mar; 19(1):72. PubMed ID: 28356155
[TBL] [Abstract][Full Text] [Related]
4. New onset or transition of disease state of psoriatic arthritis during treatment with ustekinumab: A single-center retrospective study.
Asahina A; Umezawa Y; Momose M; Honda H; Yanaba K; Nakagawa H
J Dermatol; 2017 Dec; 44(12):1380-1384. PubMed ID: 28771778
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.
Chimenti MS; Ortolan A; Lorenzin M; Triggianese P; Talamonti M; Costa L; Caso F; Favero M; Teoli M; Galluzzo M; Scarpa R; Punzi L; Perricone R; Ramonda R
Clin Rheumatol; 2018 Feb; 37(2):397-405. PubMed ID: 29302829
[TBL] [Abstract][Full Text] [Related]
6. Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.
Gossec L; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Noël W; Nurmohamed MT; Sfikakis PP; Sharaf M; Theander E; Smolen JS
Arthritis Res Ther; 2023 Jun; 25(1):109. PubMed ID: 37353788
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison.
Letarouilly JG; Flachaire B; Labadie C; Kyheng M; Cohen N; Sellam J; Richette P; Dieude P; Claudepierre P; Fautrel B; Houvenagel E; Nguyen CD; Guyot MH; Segaud N; Marguerie L; Deprez X; Salmon JH; Baudens G; Miceli-Richard C; Gervais E; Chary-Valckenaere I; Lafforgue P; Philippe P; Loeuille D; Richez C; Tubach F; Pham T; Flipo RM
Rheumatology (Oxford); 2021 Jun; 60(6):2773-2782. PubMed ID: 33232465
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multicenter study.
Azuaga AB; Frade-Sosa B; Laiz A; Estrada P; Prior-Español A; Horcada L; Polino L; Moreno M; Moragues C; Urruticoechea-Arana A; Sellas A; Tandaipan JL; Torrente-Segarra V; Garcia-Miguel J; Ros I; Ordoñez S; Moya P; Reina D; Mateo-Soria L; Fito C; Beltrán E; Pujol M; Cuervo AM; Cañete JD; Ramírez J;
Clin Rheumatol; 2020 Oct; 39(10):2963-2971. PubMed ID: 32285259
[TBL] [Abstract][Full Text] [Related]
9. Disease Activity in Psoriatic Arthritis Index and Psoriatic Arthritis Impact of Disease Questionnaire: correlation and sensitivity to change in a real clinical setting.
Pardo E; Charca L; Alonso S; Alperi M; Arboleya L; Queiro R
Clin Exp Rheumatol; 2020; 38(5):973-977. PubMed ID: 31969229
[TBL] [Abstract][Full Text] [Related]
10. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
Araujo EG; Englbrecht M; Hoepken S; Finzel S; Kampylafka E; Kleyer A; Bayat S; Schoenau V; Hueber A; Rech J; Schett G
Semin Arthritis Rheum; 2019 Feb; 48(4):632-637. PubMed ID: 30037432
[TBL] [Abstract][Full Text] [Related]
11. Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry.
Rahman P; Zummer M; Bessette L; Baer P; Haraoui B; Chow A; Kelsall J; Kapur S; Rampakakis E; Psaradellis E; Lehman AJ; Nantel F; Osborne B; Tkaczyk C
BMJ Open; 2017 Aug; 7(8):e016619. PubMed ID: 28855200
[TBL] [Abstract][Full Text] [Related]
12. Ustekinumab in psoriatic arthritis: need for studies from real-world evidence.
Queiro R; Coto-Segura P
Expert Opin Biol Ther; 2018 Sep; 18(9):931-935. PubMed ID: 30044656
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
14. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
Perrotta FM; Marchesoni A; Lubrano E
J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.
Smolen JS; Siebert S; Korotaeva TV; Selmi C; Bergmans P; Gremese E; Joven-Ibáñez B; Katsifis G; Noël W; Nurmohamed MT; Richette P; Sfikakis PP; de Vlam K; Theander E; Gossec L
Ann Rheum Dis; 2021 Nov; 80(11):1419-1428. PubMed ID: 34162594
[TBL] [Abstract][Full Text] [Related]
16. Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study.
Perrotta FM; Delle Sedie A; Scriffignano S; Volpe P; Cordisco E; Milano N; Gabini M; Lubrano E
Reumatismo; 2020 Apr; 72(1):52-59. PubMed ID: 32292021
[TBL] [Abstract][Full Text] [Related]
17. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.
Mugheddu C; Atzori L; Del Piano M; Lappi A; Pau M; Murgia S; Zucca I; Rongioletti F
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28833973
[TBL] [Abstract][Full Text] [Related]
18. Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study.
Gossec L; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Noël W; Nurmohamed MT; Sfikakis PP; Theander E; Smolen JS
Ann Rheum Dis; 2022 Jun; 81(6):823-830. PubMed ID: 35210262
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
Lubrano E; Parsons WJ; Perrotta FM
J Rheumatol; 2016 May; 43(5):918-23. PubMed ID: 26980581
[TBL] [Abstract][Full Text] [Related]
20. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).
Iannone F; Santo L; Bucci R; Semeraro A; Carlino G; Paoletti F; Quarta L; Leucci P; Zuccaro C; Marsico A; Scioscia C; D'Onofrio F; Mazzotta D; Muratore M; Cantatore FP; Lapadula G
Clin Rheumatol; 2018 Mar; 37(3):667-675. PubMed ID: 29411182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
